Ophthalmologists discuss how advanced imaging, MIGS, and home monitoring are reshaping decision-making in complex glaucoma ...
Aims To introduce a three-dimensional (3D) trajectory model that integrates structural and functional changes over time to ...
Background/Aims The neuroprotective effect of nicotinamide (NAM) supplementation has been demonstrated in both animal models ...
PolyActiva and RareSight collaborate to create innovative therapies for rare pediatric retinal diseases, aiming to transform ...
Through 24 months, scleral bio-reinforced cyclodialysis combined with cataract surgery lowered IOP by enhancing uveoscleral outflow, according to a study published in Ophthalmology Science. "The ...
PolyActiva, a clinical-stage biopharmaceutical company pioneering a novel drug delivery technology to improve outcomes for patients with ocular conditions, and RareSight, Inc., an ...
Avisi Technologies, Inc., an ophthalmic medical device company advancing novel, sight-saving technologies, presented positive twelve-month clinical data on VisiPlate® Aqueous Shunt from the VITA Trial ...
Advancing Sight Network and Miracles In Sight today jointly announced the merger of the two organizations, which will begin ...
Expect to pay at least $1,500 per eye depending on the procedure and the equipment. If you haven't bought a new pair of ...
Among them, Lucentis® is the first anti-vascular endothelial growth factor (VEGF) drug approved for ophthalmic use in China, and has accumulated mature clinical application experience, providing ...
Q3 2025 Earnings Call October 29, 2025 4:30 PM EDTCompany ParticipantsChristopher Lewis - Vice President of Investor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback